CANbridge to Start China Phase II/III Trial of GBM Treatment

03:27 EDT 13 Apr 2018 | ChinaBio Today

CANbridge Life Sciences of Beijing was granted China approval of an IND to start a Phase II/III trial of its lead candidate, CAN008, in patients with glioblastoma multiforme (GBM). The approval was based on a small (10 patient) Phase I trial of CAN008 in Taiwan, an example of China-Taiwan regulatory cooperation. In the Taiwan trial, CAN008 did not show any safety problems. CAN008 is a TNF-blocker that is thought to restore the immune system's anti-tumor response. Two years ago, CANbridge in-licensed greater China rights to CAN008 from Germany's Apogenix. More details....

Share this with colleagues:

Original Article: CANbridge to Start China Phase II/III Trial of GBM Treatment


More From BioPortfolio on "CANbridge to Start China Phase II/III Trial of GBM Treatment"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...